Bioanalysis Zone

Challenges in antibody–drug conjugate discovery: a bioconjugation and analytical perspective


“…the mode of attachment of the payload linker to the antibody must have a perfect fit for its success.”

With the approval of Adcetris to treat Hodgkin’s lymphoma and Kadcyla to treat Her2 positive advanced breast cancer, antibody–drug conjugates (ADCs) are fast becoming a well-proven strategy to treat cancer. For successful development of ADCs, several parameters at early stages in research need careful examination.

To view restricted content, please:

Leave A Comment